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It  was  shown  in  the  companion  paper  (1)  that  a  correctly  timed  subcutaneous 
injection  of Co~ynebacterium paroum admixed  with  P815  tumor cells  on one side  of a 
mouse can cause the complete regression of a  P815 tumor growing subcutaneously on 
the contralateral side. In addition, it was shown that the expression of this therapeutic 
effect  was  associated  with  the  generation  by  the  host  of a  population  of tumor- 
sensitized  T  cells  that  were  capable  of passively  transferring  a  state  of anti-tumor 
immunity to normal recipients.  This evidence, together with the finding that the  C. 
parvum-tumor admixture had no such therapeutic effect against a tumor growing in T 
cell-deficient mice, allowed the conclusion that the therapeutic  action of C. parvum 
is based on its capacity to augment the generation of T  cell-mediated  immunity.  It 
was also shown, however, that the therapeutic action of the C. parvurn-tumor  admixture 
was limited  to tumors below a  critical size, in that the admixture was without effect 
against  a  contralateral  test  tumor that  had been  growing for 5-6 d. There  are two 
possible  reasons  for the  loss of the  test  tumor's susceptibility  to C. parvum immuno- 
therapy.  Either  the tumor becomes physically too large  for a C. parvum-potentiated 
immune  response  to  cause  its  regression,  or  the  tumor  evokes  the  generation  of a 
mechanism that actively inhibits the C. parvum-potentiated response. 
The purpose of this paper is to show that the capacity of an admixture of C. parvum 
and tumor cells to cause the rejection of a  small test tumor growing at a  distant  site 
is associated with the augmented  production of cytolytic T  ceils in the lymph node 
draining  the site of injection of the  therapeutic  admixture.  It will  also show that  a 
potentiated  cytolytic response  fails  to develop  when  the  admixture  is  injected  into 
mice bearing tumors that have been growing for 6 d. The evidence is consistent with 
the hypothesis that tumor immunotherapy with an immunopotentiator  is limited  to 
an  early  period  of tumor  growth  before  the  tumor  causes  the  host  to  generate  a 
mechanism that inhibits a potentiated immune response to tumor-associated antigens. 
Materials  and Methods 
Most of the procedures used were the same as those described in the preceding paper (1), 
except for those used to measure cellular cytotoxicity in vitro, and to deplete lymph node or 
spleen cell suspensions of B cells. 
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5tCr Release Assay.  Cellular cytotoxicity was  measured  using  a  modification of the  SlCr 
release assay described by Brunner et al. (2). Target tumor ceils were grown in RPMI  1640 
containing  15%  heat  inactivated horse  serum  (HS), I  100  U/ml  penicillin, and  100  /~g/ml 
streptomycin. These  and  other  tissue culture  reagents  were  purchased  from  Grand  Island 
Biological Co., Grand Island, N. Y. Tumor cells to be used as targets were harvested during 
log-phase growth, and  106 ceils in 0.4 ml tumor growth medium were labeled with  100/LCi 
sodium chromate  (CJS.  11; Amersham Corp., Arlington Heights, Ill.) at 37°C  for  1 h.  The 
tumors used included the P815 mastocytoma (H-2  d) and the EL-4 thymoma (H-2b), originally 
obtained from Dr. Virginia Evans, National Cancer Institute, Tissue Culture Section, Bethesda, 
Md. The YAC-1 lymphoma (H-2  a) was obtained from Dr. G. Cudkowicz, State University of 
New  York,  Buffalo, N.  Y., and  the L5178Y  (H-2d), L1210  (H-2d), and  P815Y  (H-2  d)  were 
obtained from Dr. E. F. Wheeloek, Thomas Jefferson University, Philadelphia, Pa. 
Lymph node or spleen cells were obtained by pressing finely diced pieces of spleens and 
lymph nodes through a stainless steel screen using cold Hanks' balanced salt solution containing 
10 mM morpholinopropane sulfonic acid buffer (MOPS; Sigma Chemical Co., St. Louis, Ms.) 
and antibiotics. Cells were then centrifuged and resuspended in an assay medium that consisted 
of RPMI  1640  containing  10%  HS,  MOPS,  and  antibiotics. The  assay was  performed  in 
triplicate with plates containing 96 round-bottomed wells (Flow Laboratories, Inc., Roekville, 
Md.). Each well contained 104 51Cr-labeled targets and various numbers of effector cells in a 
total volume of 200/~1 of assay medium. Unless indicated, the effector to target cell ratio used 
was 50:1. After 6 h incubation at 37°C in an atmosphere of 7% CO2, 50/11 of the supernate was 
removed from each well and counted in a Rack Gamma II gamma counter (LKB Instruments, 
Inc., Rockville, Md.). Controls for the assay included labeled target cells alone (spontaneous 
release), and labeled target cells lysed with 0.5%  Triton X-100  (total release). Triton X-100 
caused the release of >97% of the total incorporated SlCr, whereas spontaneous release ranged 
from 8 to 12% of the total release for all the targets employed. The percent specific SlCr release 
was calculated as follows: 
experimental cpm - spontaneous cpm 
x  100. 
total cpm - spontaneous cpm 
T Cell Enrichment.  Lymph node or spleen cell suspensions were enriched for T cells using the 
procedure of Mage et al. (3), which depletes B cells by adherence to plastic dishes coated with 
antisera to mouse immunoglobulin (Ig). Plastic dishes (3025;  Falcon Labware, Div. of Becton, 
Dickinson  &  Co.,  Oxnard,  Calif.)  were  coated  with  goat  anti-mouse  Ig  (N.  L.  Cappel, 
Cochranville, Pa.)  by adding 20  ml  of 0.05  M  Tris-HC1  buffer,  pH  9.5,  containing 20  ~g 
antibody/ml, and incubating the dishes at 25°C for 30 min. Unbound antibody was removed 
by washing three times with cold Dulbeceo's phosphate-buffered saline (PBS) containing 5% 
HS. Spleen cells were added in a volume of 20 ml PBS-HS at a concentration of 1.5 ×  106 cells/ 
ml and incubated at 4°C for 45 min. Unattached cells were recovered, washed in PBS-HS, and 
resuspended in the appropriate medium for assay. 
Results 
C. parvum-induced  Tumor Regression Is Associated with an Augmented Production of Cytolytic 
Cells.  It was shown in the preceding paper (1)  that implanting B6D2  Fa mice with 
P815 tumor cells admixed with C. parvum results in a  9-10-d period of tumor growth, 
followed by complete tumor regression. The experiments described in this section were 
designed to determine whether this C. parvum-induced regression was associated with 
a C. parvum-augmented production of cells capable of lysing P815 tumor cells in vitro. 
The  experiments  involved injecting the individuals of one  group  of mice in  a  hind 
footpad  with  2  ×  106  P815  cells admixed  with  100/~g  of C.  parvum,  and  those  of 
another group with 2  ×  l0  s P815 cells alone. The injections of admixture and tumor 
l Abbreviations used in this paper: HS, horse serum; MOPS, morpholinopropane  sulfonic acid buffer; PBS, 
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cells were scheduled so that the cytolytic activity of cells of all mice could be tested at 
the  same  time.  At  the  times  indicated,  tumor  size  was  measured  and  cells  of the 
draining  lymph node and  spleen  were  tested  for their  capacity to lyse ~lCr-labeled 
P815 target cells at an effector to target  ratio of 50:1. The results in Fig.  1 show, in 
agreement with those in the companion paper (1), that the tumor that emerged from 
the tumor-C, parvum admixture grew for 9-10 d and then regressed, whereas the tumor 
without C. parvum continued to grow progressively.  It can be seen, in addition,  that 
rejection of the P815 mastocytoma in the presence of C. parvum was preceded  by the 
generation  in  the  draining  lymph  node  and  spleen  of cells  capable  of lysing P815 
tumor cells in vitro. The cytolytic response to the tumor growing in the presence of C. 
parvum was  of much  greater  magnitude  than  the  cytolytic  response  to  the  tumor 
growing in the absence of C. parvum. Moreover, because the lymph node draining the 
C.  parvum-treated  tumor  contained  twice  as  many  cells  as  the  node  draining  the 
untreated tumor (2.2 ×  107 vs.  1.1  ×  107), the augmented response was much greater 
than indicated in Fig.  1. It should be noted that the cytolytic response to both tumors 
peaked at about the same time on day 10. 
Use  of  Irradiated  Tumor  Cells  to  Demonstrate  the  C.  parvum-augmented  Cytolytic 
Response.  The  problem  with  using  replicating  tumor cells  for analyzing  C. parvum 
potentiated  anti-tumor  immunity  is  that  the  quantity  of tumor  antigen  increases 
progressively as the tumor grows. To avoid this variable, the production of cytolytic 
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FI6.  1.  Evidence  that the onset of regression of a footpad tumor containing C. parvum was preceded 
by the substantial generation in the draining node and spleen of cells capable of lysing 5~Cr-labeled 
P815 target cells in vitro. The cytolytic response to the C. paroum-treated tumor was of much greater 
magnitude  than  the  eytolytic response to the  untreated  control  tumor.  Cytolytic activity  was 
measured with pooled lymph node and spleen cells from three mice at an effector to target ratio of 
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substituted  for living tumor  cells  in  the  admixture.  It  can  be  seen  in  Fig.  2  that 
injection  of  10  7  irradiated  tumor  cells  admixed  with  C.  parvum  resulted  in  the 
production of cytolytic cells in the draining node and spleen. In contrast, an injection 
of 10  7 irradiated tumor ceils alone caused no response at all. Although the shape of 
the cytolytic curve suggests that  the peak of the potentiated response to irradiated 
tumor cells was probably missed by sampling at the indicated times, it was almost 
certainly lower than that obtained with replicating tumor cells. This is consistent with 
the  knowledge that  an  admixture of irradiated  tumor cells  and  C.  parvum  gives  a 
smaller therapeutic effect against a test tumor growing at a distant site (1). 
Cytolytic Cells Are Tumor-specific T Cells.  Because the SlCr release assay can measure 
the cytolytic activity of different types of effector cells, it was important to determine 
whether  the cytolytic cells  that  are  generated  in  response  to  the  C.  parvum-tumor 
admixture  are T  cells.  Fig.  3  shows  that  this  was  the case,  as  it  can  be seen  that 
cytolytic activity was  ablated  by  pretreating  lymph  node  cells  harvested  at  peak 
response with anti-Thy-1.2 antibody and complement. This evidence is supported by 
the results of an additional experiment in which cytolytic activity was measured with 
lymph node cells enriched for T  cells by depleting Ig-bearing B cells by "panning" on 
anti-Ig-coated dishes. It can be seen in Fig. 3 that enriched T  cells were much more 
cytotytic on a cell for cell basis than whole lymph node cells. 
Fig. 3 shows, in addition, that the amount of 51Cr released from targets increased 
with time, and with larger effector to target cell ratios. Moreover, the cytolytic activity 
generated against the P815 mastocytoma was specific for this tumor, as evidenced by 
the finding that no cytolytic activity was expressed against three other DBA/2 tumors 
and a C57BL/6 tumor. However, a small amount of natural killer cell activity (anti- 
YAC-1)  was expressed by draining  lymph node cells  (3.8%  5aCr release).  Cytolytic 
spleen cells harvested from the same animals showed the same characteristics except 
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Flo.  2.  Further evidence  that  C. parvum functions to augment the  production of cytolytic cells. 
Footpad injection of 10  7 irradiated,  nonreplicating tumor cells  failed  to evoke the production of 
cytolytic cells unless the tumor cells were injected admixed with C. parvum. C.  D.  MILLS,  R. J.  NORTH, AND E.  S.  DYE 
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Fx~.  3.  Some  properties of cytolytic cells harvested at peak response from the node draining  a 
tumor growing in the presence of C. parvum. The degree of lysis of 5aCr-labeled targets depended on 
the duration of the assay and the effeetor to target ratio (A). Cytolytic activity was substantially 
increased by removing Ig-bearing cells (B), and was totally eliminated by treating the lymph node 
ceils with anti-Thy-l.2  antibody and complement (C). Cytolytic activity was directed against P815 
targets, but not against three other DBA/2 (H-26) tumors or a B6 (H-2  b) tumor (D). A small amount 
of cytolytie activity was expressed against YAC-l (H-2  a) cells (D). 
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that they expressed a greater amount of natural killer cell activity (9.8% 5XCr release). 
Moreover, the same properties were displayed by peak response cells harvested from 
mice bearing untreated progressive tumors. 
DBA/2 Mice Generate Less Cytolytic Activity than B6D2 Ft Hybrids.  All the foregoing 
results were obtained with semisyngeneic B6D2 Fa mice. The possibility that some of 
the  cytolytic  activity  was  directed  against  parental  antigens  is  discounted  by  the 
foregoing results, showing that no cytolytic activity was expressed against three other 
DBA/2 tumors. Even so, it was considered important to determine whether syngeneic 
DBA/2  mice would  respond  to the  admixture  of tumor cells  and  C. parvum in  the 
same way as B6D2 mice. The results of an experiment designed to investigate this are 
shown in Fig. 4, where it can be seen that DBA/2 mice generated less peak cytolytic 
activity than B6D2 mice (25% 51Cr release vs. 43.1%)  in response to the admixture of 
C. parvum and 2  ×  106 P815 tumor cells. It was not surprising to find, therefore, that 
tumors  growing  in  the  presence  of C. parvum in  DBA/2  mice  did  not  completely 
regress.  The reason  for this  quantitatively  smaller  response in syngeneic mice is the 
subject of an ongoing study. 
Absence of a Cytolytic Response to the  Therapeutic Admixture in Mice  Bearing Established 
Tumors.  It was shown in the companion paper  (1)  that the injection of a C. parvum- 
tumor cell admixture  failed to give a  significant therapeutic  effect against  a  contra- 
lateral  test  tumor  that  had  been  growing  for about  6  d.  In view of the  foregoing 
results, it seemed reasonable to predict that the absence of a therapeutic effect against 
a  large  test  tumor would  be associated  with  a  failure  of the  admixture  to evoke a 626  ANTI-TUMOR  ACT]ON  OF  CORYNEBACTERIUM  PARVUM 
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FIc.  4.  The cytolytic  response to the  P815  tumor growing in  the  presence of C. paroum  was of 
smaller magnitude in syngeneic DBA/2 mice than in semisyngeneic B6D2  FI mice. This smaller 
cytolytic response was associated with a substantial therapeutic effect  against the tumors, but the 
tumors failed to regress completely. 
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Fro.  5.  Effect of injecting a therapeutic admixture of C. parvum and  107 irradiated tumor cells 3 d 
before, at the time of, or 3 or 6 d after implanting a  test tumor in the contralateral  footpad. The 
later the therapeutic admixture was given with respect to implanting the test tumor, the larger the 
test tumor grew and the less complete was its regression. In all cases, a substantial cytolytic response 
was generated in the node draining the site of injection of the admixture, except when the admixture 
was injected  6 d  after implanting the test tumor. In this case,  the admixture evoked no cytolytic 
response at  all,  and  this was consistent with the absence of a  therapeutic effect  against the  test 
tumor. 
potentiated cytolytic response in the draining node and spleen. This possibility was 
tested by an experiment that measured the cytolytic response to the C. parvum-tumor 
cell admixture in the draining node and spleen when the admixture was injected 3 d 
before, at the time of, or 3 or 6 d after implanting the contralateral test tumor. In this 
experiment, irradiated tumor cells were used in the admixture. The results in Figs. 5 
and 6 show that injecting the immunotherapeutic admixture 3 d  before, at the time 
of, or 3 d  after implanting the test tumor, engendered a significant cytolytic response C.  D.  MILLS,  R.  J.  NORTH,  AND  E.  S.  DYE  627 
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Fro.  6,  Additional data from the experiment displayed in Fig. 5 showing concurrent measurements 
of the cytolytic response in the spleen and in the node draining the test tumor itself. The cytolytic 
responses in the spleen peaked at the same times as those in the node draining the site of injection 
of the admixture (Fig. 5). As with the admixture node, there was no cytolytic response at all in the 
spleen when the admixture was  injected  6  d  after  implanting the test  tumor,  and  there was a 
diminished response in the spleen when the admixture was given 3 d after implanting the test tumor. 
The bottom graph shows that injecting the admixture 3 d  before, or at the time of implanting the 
test tumor primed the node draining the test tumor for an accelerated response of large magnitude 
to test tumor antigens. 
in  the  draining  node  and  spleen,  and  resulted  in  a  significant  therapeutic  effect 
against the contralateral test tumor. However, in spite of the fact that the magnitude 
of the response was about the same in each case, the later the admixture was given, 
the later the cytolytic response occurred and the  larger the  test  tumor grew before 
regression  began.  Consequently,  giving the  therapeutic  admixture on  the  3rd  d  of 
growth of the test tumor resulted  in only partial regression. It can be seen that the 
cytolytic responses to irradiated tumor cells plus C. parvum were somewhat larger than 
that shown in Fig.  2.  It should be noted, however, that in this experiment the mice 
were supporting the growth of an untreated test tumor in the contralateral footpad. 
The possibility must be considered, therefore, that the test tumor served to boost the 
response to the admixture. The most significant result from this experiment, however, 
was that no cytolytic response at all was evoked by the admixture when given on the 
6th d of growth of the test tumor. It can be seen that this was associated with the total 
absence of a therapeutic effect against the test tumor. 
Concurrent  measurement  of the cytolytic response in  the node  draining  the test 
tumor showed that injecting the therapeutic admixture 3 d  before, or at the time of 
implanting the test tumor, primed the host for an accelerated potentiated response in 
the  lymph node  draining  the  test  tumor itself (Fig.  6).  No such  priming occurred, 
however, when the therapeutic admixture was given on the 3rd or 6th d of growth of 
the test tumor. 
Discussion 
This paper shows,  in  agreement  with  the companion paper  (1),  that  implanting 
P815  tumor cells admixed with  C. paroum results in  the emergence of a  tumor that 
grows progressively for 9-10 d and then regresses. It shows, in addition, that the onset 628  ANTI-TUMOR ACTION OF CORYNEBACTERIUM PARVUM 
of tumor regression was preceded by a substantial generation in the draining lymph 
node and spleen of T  cells capable of specifically lysing P815  target cells in  vitro. 
Because the production of cytolytic T cells was much greater in response to the tumor 
growing in the presence of C. parvum than in response to a tumor growing alone, it is 
logical to conclude that the therapeutic action of C. parvum when admixed with tumor 
cells is based on its capacity to potentiate the production of cytolytic T  cells. This 
adjuvant action was revealed by the additional finding that gamma-irradiated tumor 
cells  failed  to  evoke the  generation  of cytolytic T  cells  unless  they were  injected 
admixed with C. parvum 
The  finding  that  progressive  growth  of the  untreated  P815  tumor  evokes  the 
generation of cytolytic T  cells confirms the  findings  of others  (4).  It  goes without 
saying that this cytolytic response was of insufficient magnitude to cause regression of 
the tumor. It is known, in this connection (R. J. North, E. S.  Dye, and C. D. Mills, 
manuscript  in preparation), that  mice bearing a  progressive P815 tumor acquire a 
state of concomitant anti-tumor immunity that is capable of inhibiting the growth of 
a P815 challenge implant. It is almost certain that this state of concomitant immunity 
is  based  on  the  cytolytic response  described  here.  It  is  apparent,  therefore,  that 
intratumor C. parvum functions to augment this concomitant immune response to a 
level that  is high enough  to cause regression of a  rapidly growing tumor. That  C. 
parvum serves to augment concomitant immunity is supplied by the additional finding 
that  the kinetics of the concomitant cytolytic immune response  (Fig.  1)  and the C. 
parvum-potentiated  response were similar, in that both responses began on about day 
4,  peaked on day  10,  and  then decayed. However, the decay of the unpotentiated 
response  occurred  in  the  face of progressive  tumor  growth  and  increasing  tumor 
antigen.  In  contrast,  the  decay of the  C. parvum-potentiated  response  followed the 
onset of tumor regression and the progressive loss of tumor antigen.  It would seem 
reasonable to conclude, therefore, that each response decayed for a  different reason. 
Presumably, the C. parvum-potentiated  response decayed because of the destruction of 
tumor antigen, which may have occurred much more rapidly than indicated by the 
curve for regression. In fact, the kinetics and magnitude of the C. parvum-potentiated 
response to the P815 mastocytoma are similar to the kinetics and magnitude of the 
cytolytic response to allografts (5, 6). The decay of the unpotentiated response to the 
P815 tumor, on the other hand, occurs with increasing tumor load and tumor antigen: 
a  situation that  is said to favor the generation of suppressor T  cells (7-9). Evidence 
that  the response decays because of the emergence of suppressor T  cells is seen in 
recent findings from this laboratory (10,  11), which show that progressive growth of 
the  P815  tumor,  and  of a  syngeneic fibrosarcoma,  results  in  the  generation  of a 
mechanism of T  cell-mediated immunosuppression that prevents attempts to regress 
these tumors by the passive transfer of  tumor-sensitized T cells. Recent passive transfer 
experiments  (E.  S.  Dye, R. J.  North, and  C.  D.  Mills,  manuscript  in preparation) 
have shown, moreover, that the generation of suppressor T  cells occurs on about day 
9  of growth of the  P815  mastocytoma, which  is  about  the  time that  the cytolytic 
response  begins  to  decay.  It  would  seem  reasonable  to  conclude,  therefore,  that 
concomitant immunity decays because of the tumor-induced generation of suppressor 
T  cells. 
It is too early to conclude, however, that suppressor T  cells are responsible for the 
development of refractoriness of a  progressive P815 tumor to the therapeutic action C. D. MILLS, R. J.  NORTH, AND E. S.  DYE  629 
of an admixture of C. parvum and irradiated tumor cells injected at a  distant site. It 
was shown that although injecting a therapeutic admixture of C. parvum and irradiated 
tumor cells  3  d  before, at  the  time of, or 3  d  after implanting  a  test  tumor  in  a 
contralateral site resulted in a potentiated cytolytic response and caused complete or 
partial regression of the test tumor, no such potentiated cytolytic response or thera- 
peutic effect occurred when the admixture was injected 6 d after implanting the test 
tumor.  Keeping  in  mind  that  the  test  tumor  would  have  been  growing  for  an 
additional 4 d  before any cytolytic response to the therapeutic admixture would be 
expected to begin, it would seem reasonable to suggest that suppressor T  cells would 
be present  in  large  enough  numbers  to  suppress  a  C. parvum-potentiated  cytolytic 
response. The alternative possibility exists, however, that  the response to the thera- 
peutic admixture failed to occur because of the development of  concomitant immunity 
to  the  test  tumor.  This  could  serve  to  abort  the  immunotherapeutic  response  by 
destroying the irradiated tumor cells in the admixture. In fact, there is evidence (12, 
13) that this is the reason for the failure to obtain a cytolytic response to a secondary 
allograft  that  is  given  too  soon  after  the  primary  graft  is  rejected.  It  is  possible, 
therefore, that  a  paradoxical situation exists in which the progressive growth of a 
primary tumor evokes the generation of a state of concomitant immunity, which by 
virtue of its  capacity to  destroy a  challenge  implant  of tumor  cells  is  capable  of 
destroying tumor cells injected as an admixture with an immunoadjuvant. Sooner or 
later, however, concomitant immunity decays, as suggested by the loss of cytolytic T 
cells shown in this study, and this decay is almost certainly caused by a  mechanism 
of T  cell-mediated immunosuppression,  as shown by previous studies  (10,  11).  It is 
suggested, therefore, that immunosuppression eventually becomes the major obstacle 
to immunotherapy of established tumors with C. parvum and other immunoadjuvants. 
The loss of susceptibility of progressive tumors to intralesional therapy with immu- 
noadjuvants is obviously not caused by an absence of tumor antigen at  the site of 
adjuvant injection. It must be caused, instead, by the failure of the immunoadjuvant 
to potentiate a  large enough anti-tumor immune response. The response to intrale- 
sional C. parvum therapy is currently under study in this laboratory. 
Summary 
It was shown that subcutaneous implantation of P815 tumor cells admixed with 
Corynebacterium paroum resulted in the emergence of a tumor that grew for 9-10 d and 
then  regressed.  The  onset  of tumor  regression  was  preceded  by  the  substantial 
generation in the draining lymph node and spleen of T  cells capable of specifically 
lysing P815  target cells  in  vitro. The finding  that  the  magnitude  of this  cytolytic 
response was much greater than the cytolytic response to a control tumor that grew 
progressively is consistent with the hypothesis that the anti-tumor action of C. pareum 
is based on its capacity to augment  the production of T  cells sensitized to tumor- 
specific transplantation antigens. This adjuvant action of C. pawum was revealed by 
additional experiments in which irradiated, nonreplicating tumor cells were substi- 
tuted for living tumor cells in the admixture. The results support the conclusion that 
the  potentiated  cytolytic  response  to  subcutaneous  injection  of an  admixture  of 
irradiated tumor cells and C. parvum is responsible for the ability of this admixture to 
cause the regression of a  test tumor growing at a  distant site. Finally, it was shown 
that  the failure of the therapeutic admixture to cause the regression of distant  test 630  ANTI-TUMOR ACTION OF CORYNEBACTERIUM  PARVUM 
tumors above a certain size was associated with a  failure of the admixture  to cause a 
potentiated,  anti-tumor  cytolytic  response.  We  discussed  the  possibility  that  this 
failure was caused by the presence of a  tumor-induced state of immunosuppression. 
Received  for publication 4 May 1981. 
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